Prediction: These Dividend Stocks Could Outperform Growth Stocks in the Next Decade

The article identifies AbbVie (ABBV) and Apple (AAPL) as two dividend-paying companies positioned to outperform traditional growth stocks over the next decade. AbbVie, a Dividend King, is expected to drive sustained revenue growth through its immunology drugs Skyrizi and Rinvoq, successfully navigating patent cliffs and securing Rinvoq's U.S. exclusivity until 2037. Apple, transitioning from a pure growth stock, is projected to leverage its vast user ecosystem and expanding high-margin services segment, alongside a robust dividend program with significant room for future increases, to deliver strong long-term returns.

Analysis

The article highlights AbbVie (ABBV) and Apple (AAPL) as dividend-paying entities with potential to outperform growth-oriented peers over the next decade, reflecting a strongly positive sentiment (0.75). AbbVie, a Dividend King with 53 consecutive years of dividend increases and a 2.8% forward yield, demonstrates robust capital return policies and a reasonable 61.8% cash payout ratio.

AbbVie's future growth is underpinned by its immunology drugs Skyrizi and Rinvoq, expected to drive strong sales and mitigate the Humira patent cliff. Rinvoq's U.S. patent exclusivity is secured until 2037, and new product launches are anticipated, ensuring no significant loss of exclusivity through the decade. This diversified revenue stream positions ABBV as a defensive play, having outperformed the Vanguard S&P 500 Growth ETF over the last decade.

Apple (AAPL), while no longer solely a growth stock, is projected to deliver strong returns by leveraging its extensive ecosystem of over 2 billion devices and expanding high-margin services segment, which boasts over 1 billion paid subscriptions. The recent iPhone 17 launch is expected to drive renewal cycles, further deepening its user base and enhancing overall margins.

Apple's robust financial health is evident in its low 14% cash payout ratio, indicating significant capacity for future dividend increases, having doubled its payout over the past decade. The company is also proactively addressing tariff challenges through investments in local manufacturing, positioning Apple for continued long-term value creation.

Key Decisions for Investors

• Investors seeking a blend of defensive characteristics and consistent income growth should evaluate AbbVie (ABBV) due to its Dividend King status, robust immunology pipeline, and secured patent exclusivity for key drugs.
• Consider Apple (AAPL) for long-term capital appreciation and dividend growth, driven by its expanding high-margin services segment, vast user ecosystem, and substantial capacity for future dividend increases.
• Allocate to these dividend-paying leaders as a strategic alternative to traditional growth stocks, particularly for portfolios aiming for resilient returns and income generation over the next decade.